News
AstraZeneca and Novartis emphasize US manufacturing capacity to avoid potential pharma tariffs, with Novartis aiming for 100% ...
Pfizer is expanding its multibillion-dollar cost-cutting effort that began in 2023, announcing $1.7 billion in new planned ...
Novartis reports strong Q1 2025 with $13.2B in sales, beating forecasts. Key drugs Xolair, Zolgensma, Kisqali exceed ...
AstraZeneca said it was shutting down a Phase 3 Truqap study in a hard-to-treat form of prostate cancer after an interim ...
Octagon Therapeutics, led by CEO Isaac Stoner, is shutting down after halting work on B cell immunomodulator and facing ...
As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...
Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...
A bipartisan piece of legislation proposed this week would prohibit pharma companies from receiving tax deductions for direct ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results